MedTrace Logo

Evaluation of Intensive Management Patient Aligned Care Team

NCT02932228 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 583

Last updated 2019-06-12

Study results available
· View outcomes & findings →

Summary

This evaluation will examine the feasibility, implementation, and effectiveness of a quality improvement intervention-Intensive Management Patient Aligned Care Team (ImPACT)-for high-risk patients.

Conditions

  • Primary Health Care
  • Health Care Costs

Interventions

OTHER

ImPACT

The ImPACT team offers the following services: * An intensive intake process, including a home visit if deemed appropriate * Frequent contact (in-person, telephone, or secure messaging) tailored to a patient's needs * After-hours access to on-call team member in order to avoid unnecessary emergency care * Optimization of chronic condition management using evidence-based protocols * Navigation of transitions between hospital and home * Coordination of specialty care, including contact with specialists when indicated * Rapid response to signs of health status deterioration or other stressful events * Assess patient goals, advance directives, Physician Orders for Life-Sustaining Treatment

Sponsors & Collaborators

  • VA Palo Alto Health Care System

    collaborator FED

  • Veteran Affairs Office of Patient Care Services

    collaborator FED

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Donna M Zulman, MD MS · VA Palo Alto Health Care System, Palo Alto, CA

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-01
Primary Completion
2014-06-01
Completion
2015-05-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02932228 on ClinicalTrials.gov